BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.